English | 简体中文 | 繁體中文 | 한국어
 English Press Releases
 Medicine BioTech
Size matters: Bimodal imaging receives nanoparticle enhancement
Mar 10, 2021 20:00 HKT
Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer
Mar 09, 2021 10:35 HKT
Apollomics, Inc Announces Enrollment of First Patient in Phase 1 Clinical Trial of APL-106 (uproleselan injection) in China
Mar 04, 2021 11:30 HKT
Alvotech and Cipla Gulf Expand Partnership for Commercialization of Biosimilars in Australia and New Zealand
Mar 04, 2021 10:26 HKT
Maculus Therapeutix welcomes Privity, Prepares Capital Raise for Novel Drug Delivery Platform
Feb 19, 2021 07:00 HKT
Suntrap Discovered 'LeSoleil' for COVID-19 and the Epidemic
Feb 14, 2021 20:00 HKT
Cofttek, China's Largest Manufacturer of PEA, Draws Attention of Investors
Feb 14, 2021 01:00 HKT
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
Feb 12, 2021 13:00 HKT
Novamind Announces Strategic Investment in Bionomics to Support PTSD Clinical Trial
Feb 11, 2021 21:00 HKT
Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater China
Feb 11, 2021 11:00 HKT
Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors
Feb 10, 2021 10:10 HKT
Two Immigrants, One Unique Plan For A Biopharma
Feb 03, 2021 06:00 HKT
Lasting Antiviral Effect against Covid-19 virus (SARS-CoV-2) by TAKEX CLEAN EXTRA
Feb 02, 2021 11:00 HKT
Shanghai Longyao Chief Scientist Professor Xuanming Yang published a research article on optimizing CAR-T cells function with independently expressed full-length OX40
Jan 29, 2021 08:00 HKT
China Biotech Services LY007 Cell Injection Obtained Clinical Trial Approval Letter
Jan 28, 2021 09:50 HKT
New benchmark set to deliver optimal osteoporosis care throughout Asia Pacific
Jan 28, 2021 07:00 HKT
New benchmark set to deliver optimal osteoporosis care throughout Asia Pacific
Jan 28, 2021 01:30 HKT
Heathrow Covid Chaos British Tech Co Has Solution
Jan 22, 2021 16:00 HKT
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SN1011 in China
Jan 18, 2021 08:30 HKT
APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia
Jan 07, 2021 20:10 HKT
<< Previous  Next >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: